Biotech | September 23, 2021
Aurobindo subsidiary submits MAA for oncology biosimilar
CuraTeQ Biologics is on track for filing a second oncology biosimilar
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
_256_384.jpg)
It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities
The company reports revenue growth of 26% and PAT growth of 21% YoY
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Substantial reduction in losses
The company has tied up with OrbiMed as a financial partner for global reach
The US business faced price erosion due to increased competition.
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Subscribe To Our Newsletter & Stay Updated
